Curated News
By: NewsRamp Editorial Staff
September 19, 2025
Soligenix Advances Promising Oral Mucositis Treatment SGX942
TLDR
- Soligenix's SGX942 offers a competitive edge by potentially becoming the first FDA-approved treatment for oral mucositis, reducing cancer therapy interruptions and hospitalizations.
- Soligenix is analyzing combined phase 2 and 3 data for SGX942 to design a second pivotal phase 3 study while seeking development partners for commercialization.
- SGX942 improves quality of life for cancer patients by preventing severe oral mucositis, reducing pain and enabling continued nutrition during treatment.
- Soligenix develops novel therapies using innate defense regulator technology to treat rare diseases with unmet medical needs like oral mucositis.
Impact - Why it Matters
This development matters because severe oral mucositis affects approximately 40% of patients receiving radiation therapy for head and neck cancer, causing extreme pain that often leads to treatment interruptions, nutritional challenges, and increased healthcare costs. A successful treatment like SGX942 could transform cancer care by allowing patients to maintain treatment schedules, reduce opioid dependence, and improve quality of life during therapy. For the broader pharmaceutical landscape, Soligenix's approach represents important progress in addressing rare diseases with high unmet needs, while their government-supported vaccine programs contribute to pandemic preparedness against threats like Ebola and future coronavirus variants.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its promising therapeutic candidate SGX942 (dusquetide) to address severe oral mucositis (SOM), a debilitating side effect of cancer therapy that currently lacks FDA-approved treatments. This condition often leads to hospitalization, opioid pain management, and feeding tube placement, significantly reducing patients' quality of life and potentially disrupting cancer treatment schedules. The company is currently analyzing combined phase 2 and 3 clinical trial data to design a second pivotal phase 3 study while actively seeking development partners to accelerate this critical program.
Beyond SGX942, Soligenix maintains a diverse portfolio through its Specialized BioTherapeutics and Public Health Solutions business segments. The company is developing HyBryte (SGX301) for cutaneous T-cell lymphoma, with plans to seek global regulatory approvals following successful phase 3 studies. Additional programs include expanding synthetic hypericin into psoriasis treatment, developing SGX945 for Behçet's disease, and advancing vaccine candidates for ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 through its CiVax program. These efforts are supported by government funding from agencies including NIAID, DTRA, and BARDA, leveraging the company's proprietary ThermoVax heat stabilization technology platform.
The news was distributed through InvestorWire, part of the Dynamic Brand Portfolio at IBN, which provides comprehensive financial communications services including press release syndication, editorial distribution to over 5,000 outlets, and social media reach to millions of followers. For investors seeking the latest updates on SNGX, additional information is available through the company's dedicated newsroom, providing ongoing transparency about Soligenix's progress in addressing critical unmet medical needs in rare diseases and public health threats.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Advances Promising Oral Mucositis Treatment SGX942
